Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Pharma
NICE rejects Vertex, CRISPR's Casgevy, asks for more data
In its draft guidance, the U.K.'s cost watchdog recognized the need for the sickle cell therapy but needs more data from Vertex on its effectiveness.
Zoey Becker
Mar 14, 2024 11:24am
Michigan Medicaid signs deal with bluebird for SCD gene therapy
Mar 11, 2024 11:00am
Pfizer eliminates 52 roles in San Francisco area
Jan 29, 2024 9:58am
FDA approves Vertex, CRISPR's Casgevy for beta thalassemia
Jan 16, 2024 3:40pm
Bluebird pushes Lyfgenia's US coverage to nearly 200M people
Jan 4, 2024 11:15am
High-profile Casgevy launch could face supply hitches: doctor
Dec 21, 2023 11:46am